Clinical Cardiovascular

RVX-208 our lead ApoA-I production small molecule, is the first epigenetic BET inhibitor to be tested in humans for the treatment of atherosclerosis. We are targeting the 30 million high-risk cardiovascular patients with atherosclerosis who are at most risk for major adverse events such as heart attack, stroke and sudden death. Our SUSTAIN Phase 2b trial has illustrated highly statistical significance in key markers of reverse cholesterol transport. Our ongoing Phase 2b trial ASSURE utilizes intravascular ultrasound (IVUS) technology that provides images of how RVX-208 impacts atherosclerosis inside the coronary arteries of these patients. Statistically significant regression of atherosclerosis in this patient group following six months of treatment would represent an unprecedented value proposition for the innovative pharmaceutical industry.

Epigenetics Platform

We are leaders in the field of epigenetics and BET inhibition, surpassing 5 years of clinical experience with RVX-208. This knowledge has enabled us to develop new preclinical compounds for additional therapeutic areas such as autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. Our focus and passion is to build effective collaborations with partners that deliver breakthrough medicines to improve people’s lives.

Business Development Contact

Kenneth Lebioda
Senior VP Business & Corporate Development
Email: ken@resverlogix.com
Phone: 403-254-9252 ext. 227